Supplementary Table 1. TRADITIONAL AND LUPUS-RELATED ATHEROSCLEROTIC RISK FACTORS AT BASELINE (EXCLUDING PATIENTS WITH ESRD)			
Variable	**≥140/90mmHg (n=145)**	**130-139/80-89mmHg (n=303)**	**<130/80mmHg (n=1054)**	**p**
Age (y)	47.3 ± 14.8	39.9 ± 13.3	33.4 ± 12.1	<0.001
Females (n, %)	117 (80.7%)	254 (83.8%)	95 (90.1%)	<0.001
Caucasians (n, %)	115 (79.3%)	220 (72.6%)	647 (61.4%)	<0.001
Blacks (n, %)	20 (13.8%)	37 (12.2%)	150 (14.2%)	
Others (n, %)	10 (6.9%)	46 (15.2%)	257 (24.4%)	
Adjusted mean BP (mmHg)	149/90	129/82	112/71	<0.001
Diabetes (n, %)	17 (11.7%)	17 (5.6%)	23 (2.2%)	<0.001
Dyslipidemia* (n, %)	88 (60.7%)	117 (38.6%)	194 (18.4%)	<0.001
Total cholesterol (mmol/l)	6.0 ± 1.8	5.1 ± 1.3	4.5 ± 1.1	<0.001
Smoking (current, n, %)	34 (23.4%)	56 (18.5%)	159 (15.1%)	0.003
Disease duration (y)	5.4 ± 5.9	6.6 ± 6.7	6.0 ± 6.1	0.125
SLEDAI-2K	5.2 ± 4.9	5.2 ± 5.6	4.2 ± 4.4	<0.001
SDI	0.8 ± 1.1	0.6 ± 1.0	0.5 ± 0.9	<0.001
eGFR (ml/min/1.73m^2)	74.6 ± 27.2	88.9 ± 29.7	102.6 ± 28.5	<0.001
aPL** (n, %)	53 (36.6%)	82 (27.1%)	243 (23.1%)	0.001
Antimalarials (n, %)	47 (32.4%)	170 (56.1%)	717 (68.0%)	<0.001
Glucocorticosteroids (GCS) (n, %)	119 (82.1%)	219 (72.3%)	684 (64.9%)	<0.001
Cumulative GCS dose (g)***	15.3 ± 18.6	17.1 ± 19.1	15.3 ± 18.6	0.414
Antihypertensives (n, %)	51 (35.2%)	86 (28.4%)	164 (15.6%)	<0.001
Antiplatelets/Anticoagulants (n, %)	7 (4.8%)	18 (5.9%)	91 (8.6%)	0.117

P values: trend from ANOVA for continuous variables, Chi-square test for categorical variables
*Abnormal total cholesterol or low-density lipoprotein for two consecutive visits
** Lupus anticoagulant and/or anticardiolipin antibodies (IgM, IgG)
***From enrolment up to the baseline
SLEDAI-2K: SLE Disease Activity Index 2000, SDI: Systemic Lupus International Collaborating Clinics Damage Index, eGFR:

estimated glomerular filtration rate, aPL: antiphospholipid antibodies

Supplementary Table 2. UNI- AND MULTIVARIABLE TIME DEPENDENT COX REGRESSION ANALYSIS FOR PREDICTORS OF AVEs (excluding patients with ESRD)						
	Univariable analysis			Multivariable analysis		
Variable	HR	95% CI	*p*	HR	95% CI	*p*
Stage 1 hypertension vs. normotensives	1.69	1.11-2.57	0.015	**1.64**	**1.06-2.52**	**0.0246**
Stage 2 hypertension vs. normotensives	1.99	1.25-3.18	0.0038	**1.66**	**1.02-2.71**	**0.0417**
Age	1.06	0.94-1.20	0.3107	2.06	0.95-4.46	0.0656
Age-squared	1.00	1.00-1.00	0.4132	0.99	0.99-1.00	0.0707
Female	0.50	0.31-0.81	0.005	0.70	0.42-1.17	0.1700
Caucasian	1.24	0.78-1.95	0.3592	1.26	0.78-2.04	0.3451
Diabetes	1.64	0.93-2.88	0.0862	1.32	0.73-2.36	0.3576
Dyslipidemia*	2.55	0.58-11.27	0.216	1.71	0.33-8.89	0.5209
Smoking	1.64	1.05-2.56	0.0283	**1.86**	**1.17-2.96**	**0.0088**
SLEDAI-2K	1.11	1.07-1.15	<.0001	**1.10**	**1.06-1.15**	**<.0001**
eGFR	0.99	0.99-1.00	0.0593	1.00	0.99-1.00	0.4157
Antiphospholipid antibodies**	1.74	1.17-2.59	0.0061	1.41	0.93-2.12	0.1036
Glucocorticoids	2.06	1.42-2.99	0.0002	**1.79**	**1.21-2.65**	**0.0036**
Anticoagulants/Antiplatelets	2.88	1.96-4.23	<.0001	**3.14**	**2.11-4.68**	**<.0001**
*Abnormal total cholesterol or low-density lipoprotein for two consecutive visits ** Lupus anticoagulant and/or anticardiolipin antibodies (IgM, IgG) SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000, eGFR: estimated glomerular filtration rate						